Omega-3 Global Organization
This article was originally published in The Tan Sheet
Executive Summary
Vendors launch trade group for increasing regulatory approvals for EPA- and DHA-based products, developing education strategies and consumer awareness and implementing quality standards that will protect omega-3 EPA/DHA brands at Natural Products Expo East in Baltimore Oct. 4-7. The Global Organization for EPA & DHA Omega-3 (GOED Omega-3) includes processors, refiners, manufacturers, distributors, marketers and retailers as well as healthcare professionals, educators and researchers. GOED Omega-3 will take on a broader mandate than CRN's now-dissolved Omega-3 Working Group, but will also build on its accomplishments, including product-quality focus and industry acceptance of the voluntary Omega-3 monograph, the group says. GOED Omega-3's start-up committee includes Robert Orr, president and CEO of Ocean Nutrition Canada; Philip Fass, vice president of sales/marketing at Martek Biosciences; Bjorn Rene, vice president of sales at Napro Pharma; and Ian Newton, president of Ceres Consulting...
You may also be interested in...
Companies Develop More “Cost-Effective” Non-Fish Omega-3 Products
Industry demand for cost-effective omega-3 oils for food and beverage applications has led several companies to start innovative research and development of non-fish-derived oils
GOED Omega-3 moves forward
The Global Organization of EPA and DHA Omega-3 launched its Web site, goedomega3.com, Feb. 9 to "inform members, science media, health professionals, trade marketers and retailers" about the organization, its mission and its membership benefits. The international trade association's goal is to have 50 companies join before the end of 2007. Currently the group has 21 members including Martek Biosciences, Cargill and DSM Nutritional Products. Also, in November 2006 GOED Omega-3 elected its board of directors including Philip Fass from Martek and Ian Newton from Ceres Consulting. Robert Orr of Ocean Nutrition Canada chairs the board and Thomas Grys of Denomega is vice chair. The group formed in October (1"The Tan Sheet" Oct. 9, 2006, In Brief)...
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.